Genus Oncology has also filed an investigational new drug (IND) application with the US Food & Drug Administration (FDA).
The prospective, open-label Phase I trial is designed to determine the safety and tolerability, and potential anti-tumour activity of GO-203-2c.
The study will enroll up to 40 patients at multiple clinical sites.
GO-203-2c is the optimized lead peptide drug candidate synthesised to target MUC1, an oncoprotein that is over-expressed in many diverse human carcinomas.